MDCO The Medicines Company

19.06
-0.7  -4%
Previous Close 19.76
Open 19.26
Price To Book -52.94
Market Cap 1407813075
Shares 73,862,176
Volume 4,884,585
Short Ratio
Av. Daily Volume 1,135,285

SEC filingsSee all SEC filings

  1. 8-K - Current report 181234487
  2. 8-K - Current report 181231624
  3. 8-K - Current report 181231580
  4. 8-K - Current report 181229511
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170486

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrollment announced February 20, 2018 enrollment to be completed 1H 2018. Data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)

SEC Filings

  1. 8-K - Current report 181234487
  2. 8-K - Current report 181231624
  3. 8-K - Current report 181231580
  4. 8-K - Current report 181229511
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170486
  6. 8-K - Current report 181168276
  7. 8-K - Current report 181042193
  8. CT ORDER - Confidential treatment order 181039558
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986855
  10. 8-K - Current report 18983101